A Study of LXI-15029 in Patients With Advanced Malignant Solid Tumors

  • STATUS
    Recruiting
  • participants needed
    72
  • sponsor
    Shandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Updated on 8 December 2021
estrogen
measurable disease
tumor cells
epidermal growth factor receptor
human epidermal growth factor
erbb2
epidermal growth factor
estrogen receptor
lxi-15029
exemestane
locally advanced breast cancer

Summary

  1. To evaluate the safety and tolerability of LXI-15029 in Chinese patients with advanced malignant solid tumors in monotherapy period, including confirmation of the maximum tolerated dose (MTD) of monotherapy. 2.To evaluate the safety and tolerability of LXI-15029 in Chinese postmenopausal patients with metastatic or locally advanced breast cancer with estrogen receptor (+) and human epidermal growth factor receptor 2 (-) in combined with Exemestane period , including confirmation of the maximum tolerated dose(MTD) of the combined therapy with Exemestane.

Details
Condition Advanced Breast Cancer
Treatment LXI-15029, LXI-15029+Exemestane
Clinical Study IdentifierNCT03125746
SponsorShandong Luoxin Pharmaceutical Group Stock Co., Ltd.
Last Modified on8 December 2021

Similar trials to consider

Loading...

Browse trials for

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name

Added by • 

 • 

Private

Reply by • Private
Loading...

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.
Loading...

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note